rofecoxib has been researched along with Pregnancy in 12 studies
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated the effects of treatment with rofecoxib, a cyclooxygenase-2 inhibitor, on sperm quality and pregnancy rate after intrauterine insemination (IUI) or monitored intercourse." | 3.74 | Sperm quality and pregnancy rate after COX-2 inhibitor therapy of infertile males with abacterial leukocytospermia. ( De Leo, V; Focarelli, R; Gambera, L; Morgante, G; Piomboni, P; Serafini, F, 2007) |
| "Rofecoxib has a significant but reversible effect on fetal renal function and the ductus arteriosus." | 2.71 | TOCOX--a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk. ( Bennett, PR; Groom, KM; Jones, BA; Seed, P; Shennan, AH, 2005) |
| "Rofecoxib use was associated with an increased risk for preterm birth and preterm premature rupture of membranes (PPROM)." | 2.48 | Cyclo-oxygenase (COX) inhibitors for preventing preterm labour. ( Khanprakob, T; Laopaiboon, M; Lumbiganon, P; Sangkomkamhang, US, 2012) |
| " RATIONALE FOR THE USE OF SELECTIVE COX-2 INHIBITORS: The rationale for the prescription of selective COX-2 inhibitors as neuroprotective drugs in AD lies on: Epidemiological data having shown a reduced risk of developing AD in patients treated with anti-inflammatory doses of classical NSAIDs (inhibition of COX-1 and COX-2) but not with antithrombotic doses of aspirin (selective inhibition of COX-1), Cellular experiments, Demonstration of a better gastro-intestinal (GI) safety profile with selective COX-2 inhibitors than with classical NSAIDs in short-term studies, allowing a possible long-term use in AD." | 2.41 | [Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives]. ( Blain, A; Blain, H; Jeandel, C; Jouzeau, JY; Netter, P; Terlain, B; Touchon, J; Tréchot, P, 2000) |
| "Rofecoxib has a potent tocolytic effect in vitro." | 1.31 | In vitro study of tocolytic effect of rofecoxib, a specific cyclo-oxygenase 2 inhibitor. Comparison and combination with other tocolytic agents. ( Benchaib, M; Doret, M; Gharib, C; Mellier, G; Pasquier, JC; Piacenza, JM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 9 (75.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khanprakob, T | 1 |
| Laopaiboon, M | 1 |
| Lumbiganon, P | 1 |
| Sangkomkamhang, US | 1 |
| Doret, M | 1 |
| Mellier, G | 1 |
| Benchaib, M | 1 |
| Piacenza, JM | 1 |
| Gharib, C | 1 |
| Pasquier, JC | 1 |
| Wilkinson-Berka, JL | 1 |
| Alousis, NS | 1 |
| Kelly, DJ | 1 |
| Gilbert, RE | 1 |
| Howard, BC | 1 |
| Kovac, CM | 1 |
| Calhoun, BC | 1 |
| Hoeldtke, NJ | 1 |
| Napolitano, PG | 1 |
| Hegi, TR | 1 |
| Bombeli, T | 1 |
| Seifert, B | 1 |
| Baumann, PC | 1 |
| Haller, U | 1 |
| Zalunardo, MP | 1 |
| Pasch, T | 1 |
| Spahn, DR | 1 |
| McWhorter, J | 1 |
| Carlan, SJ | 1 |
| OLeary, TD | 1 |
| Richichi, K | 1 |
| OBrien, WF | 1 |
| Chan, VS | 1 |
| Groom, KM | 1 |
| Shennan, AH | 1 |
| Jones, BA | 1 |
| Seed, P | 1 |
| Bennett, PR | 1 |
| Gambera, L | 1 |
| Serafini, F | 1 |
| Morgante, G | 1 |
| Focarelli, R | 1 |
| De Leo, V | 1 |
| Piomboni, P | 1 |
| Rodgers, E | 1 |
| Blain, H | 1 |
| Jouzeau, JY | 1 |
| Blain, A | 1 |
| Terlain, B | 1 |
| Tréchot, P | 1 |
| Touchon, J | 1 |
| Netter, P | 1 |
| Jeandel, C | 1 |
| Jeske, AH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia[NCT00442676] | Phase 2 | 0 participants (Actual) | Interventional | 2009-06-30 | Withdrawn (stopped due to No patients were recruited. Treatment drug expired.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for rofecoxib and Pregnancy
| Article | Year |
|---|---|
Cyclo-oxygenase (COX) inhibitors for preventing preterm labour.
Topics: Adult; Cyclooxygenase 2 Inhibitors; Female; Humans; Lactones; Obstetric Labor, Premature; Pregnancy; | 2012 |
A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Fem | 2004 |
Treating pain with COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Costs; Drug Inte | 1999 |
[Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives].
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain | 2000 |
COX-2 inhibitors and dental pain control.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Contraindications; Cyclooxygenase Inhibitors; Fa | 1999 |
3 trials available for rofecoxib and Pregnancy
| Article | Year |
|---|---|
Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac.
Topics: Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Blood Loss, S | 2004 |
Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial.
Topics: Administration, Oral; Adult; Cyclooxygenase Inhibitors; Female; Humans; Lactones; Magnesium Sulfate; | 2004 |
TOCOX--a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk.
Topics: Adult; Blood Flow Velocity; Cyclooxygenase Inhibitors; Double-Blind Method; Ductus Arteriosus; Femal | 2005 |
4 other studies available for rofecoxib and Pregnancy
| Article | Year |
|---|---|
In vitro study of tocolytic effect of rofecoxib, a specific cyclo-oxygenase 2 inhibitor. Comparison and combination with other tocolytic agents.
Topics: Analysis of Variance; Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycl | 2002 |
COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, A | 2003 |
The effects of a cyclo-oxygenase II inhibitor on placental artery production of thromboxane and prostacyclin.
Topics: Angiotensin II; Arteries; Culture Media; Culture Techniques; Cyclooxygenase 2; Cyclooxygenase 2 Inhi | 2003 |
Sperm quality and pregnancy rate after COX-2 inhibitor therapy of infertile males with abacterial leukocytospermia.
Topics: Adult; Cyclooxygenase 2; Female; Humans; Infertility, Male; Lactones; Leukocytes; Male; Pregnancy; P | 2007 |